Hennion & Walsh Asset Management Inc. Raises Stock Holdings in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY)

Hennion & Walsh Asset Management Inc. lifted its stake in shares of Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY - Free Report) by 38.3% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 75,072 shares of the company's stock after buying an additional 20,798 shares during the quarter. Hennion & Walsh Asset Management Inc. owned about 0.13% of Harmony Biosciences worth $2,583,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors also recently modified their holdings of the company. Mirae Asset Global Investments Co. Ltd. grew its position in Harmony Biosciences by 21.2% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,056 shares of the company's stock valued at $80,000 after purchasing an additional 360 shares during the period. GAMMA Investing LLC grew its position in Harmony Biosciences by 92.6% in the 4th quarter. GAMMA Investing LLC now owns 907 shares of the company's stock valued at $31,000 after purchasing an additional 436 shares during the period. Profund Advisors LLC lifted its stake in Harmony Biosciences by 11.1% during the 2nd quarter. Profund Advisors LLC now owns 7,557 shares of the company's stock valued at $228,000 after acquiring an additional 758 shares in the last quarter. CWM LLC lifted its stake in Harmony Biosciences by 111.7% during the 3rd quarter. CWM LLC now owns 1,469 shares of the company's stock valued at $59,000 after acquiring an additional 775 shares in the last quarter. Finally, Mendota Financial Group LLC lifted its stake in Harmony Biosciences by 24,125.0% during the 4th quarter. Mendota Financial Group LLC now owns 969 shares of the company's stock valued at $33,000 after acquiring an additional 965 shares in the last quarter. Institutional investors and hedge funds own 86.23% of the company's stock.

Harmony Biosciences Stock Performance

Harmony Biosciences stock traded up $0.51 during midday trading on Friday, reaching $39.05. The stock had a trading volume of 601,854 shares, compared to its average volume of 528,396. Harmony Biosciences Holdings, Inc. has a 12 month low of $28.14 and a 12 month high of $41.61. The firm's 50-day moving average price is $34.34 and its 200 day moving average price is $34.78. The firm has a market capitalization of $2.23 billion, a PE ratio of 18.51, a P/E/G ratio of 0.49 and a beta of 0.78. The company has a quick ratio of 3.20, a current ratio of 3.24 and a debt-to-equity ratio of 0.28.

Harmony Biosciences (NASDAQ:HRMY - Get Free Report) last announced its quarterly earnings data on Tuesday, October 29th. The company reported $0.79 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.64 by $0.15. Harmony Biosciences had a return on equity of 23.16% and a net margin of 17.98%. The business had revenue of $186.00 million for the quarter, compared to analysts' expectations of $184.07 million. During the same period in the previous year, the business posted $0.63 EPS. The firm's quarterly revenue was up 16.0% compared to the same quarter last year. As a group, research analysts predict that Harmony Biosciences Holdings, Inc. will post 2.42 earnings per share for the current fiscal year.

Analyst Ratings Changes

HRMY has been the topic of several recent analyst reports. HC Wainwright restated a "buy" rating and set a $75.00 price objective on shares of Harmony Biosciences in a research note on Thursday. Needham & Company LLC restated a "buy" rating and set a $52.00 price objective on shares of Harmony Biosciences in a research note on Monday. Oppenheimer reiterated an "outperform" rating and set a $59.00 target price (up from $56.00) on shares of Harmony Biosciences in a research note on Wednesday, October 30th. Mizuho lifted their target price on Harmony Biosciences from $42.00 to $52.00 and gave the stock an "outperform" rating in a research note on Thursday, October 10th. Finally, Raymond James reiterated an "outperform" rating and set a $40.00 target price on shares of Harmony Biosciences in a research note on Thursday, October 10th. Eight investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock presently has a consensus rating of "Buy" and an average target price of $55.00.

Insider Buying and Selling at Harmony Biosciences

In other Harmony Biosciences news, insider Jeffrey Dierks sold 21,496 shares of Harmony Biosciences stock in a transaction dated Tuesday, October 29th. The stock was sold at an average price of $40.47, for a total transaction of $869,943.12. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 30.80% of the company's stock.

About Harmony Biosciences

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.